Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of PCSK9 Inhibitor Therapeutics

http://academiccme.com/wp-content/uploads/2017/06/FH-125-x-125.jpg

Course Information

Therapautic Area: Cardiology
Format(s): Webcast
Credit(s): 2.00 AMA PRA Category 1 Credit(s)™
Activity Dates: May 30, 2017 - May 29, 2018

 

Program Overview

This educational content was derived from the American College of Physicians Internal Medicine Meeting 2017 in San Diego, California. This activity will focus on optimized treatment plans for patients with dyslipidemia in the era of PCSK9 inhibitor therapeutics. LDL-C has been identified as an important therapeutic target to prevent the progression of atherosclerotic disease, however only 1 out of every 3 adults with high LDL-C has the condition under control. Expert faculty on this panel will discuss the science of PCSK9 inhibitors and aid physicians in the best practices to get their patients at LDL-C target.

Target Audience

Cardiologists, internists, primary care physicians, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.

Learning Objectives

  1. Discuss the science of PCSK9 inhibitor therapeutics and the current ACC/AHA/NLA guidelines for patients with dyslipidemia.
  2. Analyze clinical trial data for PCSK9 inhibitor therapeutics.
  3. Integrate personalized treatment plans for patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.

Faculty


Underberg high res
James A. Underberg, MD
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, New York

 

maxresdefaultMichael J. Blaha, MD
Assistant Professor of Medicine
Johns Hopkins School of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Baltimore, Maryland

 

Jackson HeadshotElizabeth J. Jackson MSN, ACNS-BC, FNLA
Diplomate, Accreditation Council of Clinical Lipidology
Cardio Texas PLLC
St. David’s Medical Center
Austin, TX

 

Jones_Peter

Peter H. Jones, MD
Associate Professor Medicine
Center for Cardiovascular Disease Prevention
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
Baylor College of Medicine
Houston, TX, US

 


Registration



This CME activity has been supported by an independent educational grant from Amgen Inc.

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

eocme acme logo